Octreotide Acetate Injection Small Volume Parenteral 0.1 mg
Product : Octreotide Acetate Injection
Specification : 0.1mg
Standard : In - house
Packing : 5vials/box
Octreotide is the acetate salt of a cyclic octapeptide. It is a
long-acting octapeptide with pharmacologic properties mimicking
those of the natural hormone somatostatin
Indications and Dosages :
➤➤To control symptoms associated with vasoactive intestinal peptide
tumors (watery diarrhea) and metastatic carcinoid tumors (diarrhea
Adults currently receiving subcutaneous injections. 20 mg every 4 wk for 2 mo, with subcutaneous doses continued for 2
to 4 wk after I.M. injections start. If patient has positive
response to initial 2-mo regimen, dosage reduced to 10 mg every 4
wk. If symptoms persist or increase after initial 2-mo regimen,
dosage increased to 30 mg every 4 wk, as prescribed.
Adults. Initial: 200 to 300 mcg daily in divided doses twice daily to four
times a day, for first 2 wk. Maintenance: Individualized. Maximum:
450 mcg daily.
➤➤To treat symptoms of acromegaly, to suppress the release of
growth hormone from pituitary tumors
i.v. or subcutaneous injection
Adults. Initial: 50 mcg three times a day Usual: 100 mcg three times a day
Maximum: 1,500 mcg daily.
Adults currently receiving subcutaneous injections. 20 mg every 4 wk for 3 mo; then adjusted as prescribed in response
to serum growth hormone level. Maximum: 40 mg every 4 wk.
Route Onset Peak Duration
SubQ Unknown Unknown Up to 12 hr
Octreotide exerts pharmacologic actions similar to the natural
hormone, somatostatin. It is an even more potent inhibitor of
growth hormone, glucagon, and insulin than somatostatin. Like
somatostatin, it also suppresses leuteinizing hormone (LH) response
to GnRH, decreases splanchnic blood flow, and inhibits release of
serotonin, gastrin, vasoactive intestinal peptide, secretin,
motilin, and pancreatic polypeptide. Octreotide has been used to
treat the symptoms associated with metastatic carcinoid tumors
(flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP)
secreting adenomas (watery diarrhea). Octreotide substantially
reduces and in many cases can normalize growth hormone and/or IGF-1
(somatomedin C) levels in patients with acromegaly.
Mechanism of action :
Octreotide binds to somatostatin receptors. These receptors are
coupled via pertussis toxin sensitive G proteins which lead to
inhibition of adenylyl cyclase. Octreotide binding to these
receptors also stimulates phosphotyrosine phosphatase and
activation of the Na(+)/H(+) exchanger via pertussis toxin
insensitive G proteins.